Article
Distribution of the immunohistochemical expression of BAP1 in meningiomas
Die Verteilung der immunohistochemischen Expression von BAP1 in Meningeomen
Search Medline for
Authors
Published: | May 25, 2022 |
---|
Outline
Text
Objective: Meningiomas are mostly benign tumors arising from the arachnoid cap cells. However, prognostic assessment is important to identify cases with a tendency for a more aggressive behavior. The loss of the breast cancer (BRCA)1-associated protein-1 tumor suppressor gene (BAP1) has recently been described to be associated with clinically aggressive meningioma subtypes.
Methods: To evaluate the distribution of BAP1 loss in more detail we performed immohistochemical staining for BAP1 in 1253 formalin fixated paraffin embedded meningioma tissue samples that were surgically treated in the authors' institution between March 2000 and March 2017.
Results: A loss of BAP1 was only seen in 5 cases (0.4%). Most of them were more aggressive subtypes. Regarding high-grade meningiomas (WHO grade III), 3 out of 28 cases showed a BAP1 loss (10.7%). A Kaplan-Meier analysis showed a negative prognostic impact. However, the subgroup with BAP1 loss is too small for further prognostic evaluation via multivariate analysis.
Conclusion: Immunohistochemical BAP1 expression is a rare finding in meningiomas and is mainly observed in more aggressive tumor types.